Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 41,678	$ 56,464
Marketable investment	194,431
Accounts receivables, net	16,309	15,506
Inventory	1,779	1,831
Prepaid expenses	7,656	8,712
Other current assets	3,848	3,721
Total current assets	265,701	86,234
Property and equipment, net	34,681	31,861
Operating lease right-of-use assets	39,011	42,052
Intangibles, net	72,640	73,675
Goodwill	43,554	43,554
Equity investments	155,979	256,397
Other assets, net	2,049	2,049
Total assets	613,615	535,822
Current liabilities:
Accounts payable	25,060	24,706
Accrued payroll and related benefits	16,286	20,859
Accrued expenses	27,728	19,198
Current portion of deferred revenue	1,120	4,485
Current portion of operating lease liabilities	3,734	3,626
Acquisition consideration payable	398	398
Current portion of debt	21,718	23,208
Total current liabilities	96,044	96,480
Long-term debt, net of discount	79,956	92,258
Deferred tax liabilities, net	6,699	6,918
Deferred revenue	116,926	113,185
Derivative liabilities	33,200	35,400
Operating lease liabilities	49,354	50,301
Other long-term liabilities	549	549
Total liabilities	382,728	395,091
Commitments and contingencies (See Note 10)
Sorrento Therapeutics, Inc. equity
Preferred stock, $0.0001 par value; 100,000,000 shares authorized and no shares issued or outstanding
Common stock, $0.0001 par value 750,000,000 shares authorized and 285,655,428 and 275,285,582 shares issued and outstanding at March 31, 2021 and December 31, 2020, respectively	29	28
Additional paid-in capital	1,236,195	1,172,346
Accumulated other comprehensive income (loss)	445	520
Accumulated deficit	(955,769)	(958,279)
Treasury stock, 7,568,182 shares at cost at March 31, 2021, and December 31, 2020	(49,464)	(49,464)
Total Sorrento Therapeutics, Inc. stockholders’ equity	231,436	165,151
Noncontrolling interests	(549)	(24,420)
Total equity	230,887	140,731
Total liabilities and stockholders’ equity	$ 613,615	$ 535,822